Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Works Technologies AB Total Payout Ratio Chart
FRA:1BD vs ISRG, BDX, RMD: Total Payout Ratio Comparison
For the Medical Instruments & Supplies subindustry, Bio-Works Technologies AB's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Works Technologies AB Total Payout Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Works Technologies AB's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where Bio-Works Technologies AB's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Works Technologies AB (FRA:1BD) has a Total Payout Ratio of 23.26 as of Sep. 06, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Bio-Works Technologies AB and its competitors.
Is Bio-Works Technologies AB's Total Payout Ratio too high?
Bio-Works Technologies AB's current Total Payout Ratio is 23.26. Overall, Bio-Works Technologies AB has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Works Technologies AB's Total Payout Ratio compare to ISRG and BDX?
Bio-Works Technologies AB's Total Payout Ratio of 23.26 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Medical Devices & Instruments company?
A good Total Payout Ratio depends on the Medical Devices & Instruments industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Bio-Works Technologies AB and its competitors. Bio-Works Technologies AB's current Total Payout Ratio is 23.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Works Technologies AB stock overvalued right now?
Based on GuruFocus' analysis, Bio-Works Technologies AB (FRA:1BD) is currently considered Fairly Valued. The stock's GF Value™ is €0.30, compared to a current price of €0.28 — trading 6.3% below its estimated fair value. The current Total Payout Ratio is 23.26. Bio-Works Technologies AB's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Bio-Works Technologies AB (FRA:1BD), the current Total Payout Ratio is 23.26 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Works Technologies AB (FRA:1BD) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Works Technologies AB stock appears to be undervalued.
The current stock price of €0.28 is trading 6.3% below its estimated GF Value™ of €0.30.
GuruFocus considers Bio-Works Technologies AB to be Fairly Valued.
Key valuation signals for FRA:1BD:
Total Payout Ratio: 23.26
GF Value™: €0.30 vs. price of €0.28 (6.3% below fair value)
No single metric tells the full story. See the FRA:1BD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Works Technologies AB is a Sweden-based life science company which is engaged in designing, developing, manufacturing and supplying products for purification and separation of proteins and other molecules. The product line of the company includes activated resin, immobilized metal-ion affinity chromatography resin, ion exchange chromatography resin, size exclusion chromatography resin and others. The company has also developed affinity chromatography technique, BabyBio Columns, OptiBio glass columns for separating proteins, and protein purification. Bio-Works serves various end users such as academic research laboratories, biopharmaceutical companies, the food and beverage industry and others.
51GF Score
Get the complete analysis for FRA:1BD
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1BD has been successfully added to your 
